vs
Side-by-side financial comparison of Plymouth Industrial REIT, Inc. (PLYM) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $51.2M, roughly 1.4× Plymouth Industrial REIT, Inc.). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -106.3%, a 57.2% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -1.4%).
Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
PLYM vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.2M | $70.6M |
| Net Profit | $-54.4M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | -102.5% | -56.7% |
| Net Margin | -106.3% | -49.0% |
| Revenue YoY | -1.4% | 81958.1% |
| Net Profit YoY | -248.5% | 54.9% |
| EPS (diluted) | $-1.23 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $51.2M | $70.6M | ||
| Q2 25 | $47.2M | — | ||
| Q1 25 | $45.6M | — | ||
| Q4 24 | $47.6M | — | ||
| Q3 24 | $51.9M | — | ||
| Q2 24 | $48.7M | — | ||
| Q1 24 | $50.2M | — | ||
| Q4 23 | $50.8M | — |
| Q3 25 | $-54.4M | $-34.6M | ||
| Q2 25 | $-6.1M | — | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $147.4M | — | ||
| Q3 24 | $-15.6M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $6.2M | — | ||
| Q4 23 | $9.3M | — |
| Q3 25 | -102.5% | -56.7% | ||
| Q2 25 | -10.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -29.6% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | -106.3% | -49.0% | ||
| Q2 25 | -12.9% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 309.9% | — | ||
| Q3 24 | -30.1% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 12.4% | — | ||
| Q4 23 | 18.3% | — |
| Q3 25 | $-1.23 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $3.24 | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $0.03 | — | ||
| Q1 24 | $0.14 | — | ||
| Q4 23 | $0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $470.1M | $503.0M |
| Total Assets | $1.6B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $646.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $873.4M | — |
| Q3 25 | $470.1M | $503.0M | ||
| Q2 25 | $539.6M | — | ||
| Q1 25 | $571.0M | — | ||
| Q4 24 | $579.5M | — | ||
| Q3 24 | $436.5M | — | ||
| Q2 24 | $475.2M | — | ||
| Q1 24 | $484.6M | — | ||
| Q4 23 | $483.0M | — |
| Q3 25 | $1.6B | $577.1M | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — | ||
| Q4 23 | $1.4B | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.12× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 1.81× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $20.0M | $-84.6M | ||
| Q2 25 | $23.4M | — | ||
| Q1 25 | $15.6M | — | ||
| Q4 24 | $96.1M | — | ||
| Q3 24 | $17.6M | — | ||
| Q2 24 | $19.9M | — | ||
| Q1 24 | $16.6M | — | ||
| Q4 23 | $18.6M | — |
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.67× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 15.12× | — | ||
| Q1 24 | 2.67× | — | ||
| Q4 23 | 2.01× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
